Biotech News

BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market

Brainstorm Cell Therapeutics Inc. (BCLI)Brainstorm Cell Therapeutics Inc.2026-06-25 13:46 ESTFinancing

BCLI (BCLI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is bcli.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

BCLIBrainstorm Cell Therapeutics Inc.2026-06-25 13:46 EST

BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine

BCLIBrainstorm Cell Therapeutics Inc.2026-06-25 13:46 EST

BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

BCLIBrainstorm Cell Therapeutics Inc.2026-06-25 13:46 EST

BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

BCLIBrainstorm Cell Therapeutics Inc.2026-06-25 13:46 EST

BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

BCLIBrainstorm Cell Therapeutics Inc.2026-06-25 13:46 EST

BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

BCLIBrainstorm Cell Therapeutics Inc.2026-06-25 13:46 EST

Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market

BCLIBrainstorm Cell Therapeutics Inc.2026-06-25 13:46 EST

Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February

BCLIBrainstorm Cell Therapeutics Inc.2026-06-25 13:46 EST

BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

JAGXJaguar Health2026-06-25 13:46 EST

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.

Recent company news

Stock data

Close
Market cap
Exchange
NASDAQ
Sector
Biotechnology
Location
United States